Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma 2Breast Neoplasms 2Vomiting 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Sarcoma 1Postoperative Nausea and Vomiting 1Neoplasm Metastasis 1Multiple Myeloma 1Liposarcoma 1Leukemia, Hairy Cell 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Carcinoma In Situ 1Adenocarcinoma, Mucinous 1

Interventions

Fulvestrant 125Trastuzumab 114Paclitaxel 113Letrozole 108pembrolizumab 79pertuzumab 75palbociclib 75Capecitabine 72Anastrozole 72Cyclophosphamide 70Carboplatin 67abemaciclib 64exemestane 63Tamoxifen 63ribociclib 60trastuzumab deruxtecan 57Surveys and Questionnaires 51Specimen Handling 50Radiotherapy 49Docetaxel 49Magnetic Resonance Spectroscopy 48Blood Specimen Collection 40olaparib 39Standard of Care 36Biopsy 33sacituzumab govitecan 31130-nm albumin-bound paclitaxel 31Doxorubicin 30Exercise 29eribulin 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Famotidine × 1 year × Clear all
NCT02473042 2025-12-05

Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)

M.D. Anderson Cancer Center

Phase NA Completed
188 enrolled 11 charts
Breast

Breast Neoplasms, Vomiting, Postoperative Nausea and Vomiting

NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

Phase 2/3 Completed
130 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡